Holen Sie sich die Stockscreener-App
2.735
0.91%
-0.025
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$2.76
Offen:
$2.8
24-Stunden-Volumen:
4.24M
Relative Volume:
1.01
Marktkapitalisierung:
$532.01M
Einnahmen:
$36,000
Nettoeinkommen (Verlust:
$-91.08M
KGV:
-2.917
EPS:
-0.9376
Netto-Cashflow:
$-71.67M
1W Leistung:
-10.62%
1M Leistung:
-16.62%
6M Leistung:
-18.11%
1J Leistung:
-30.41%
1-Tages-Spanne:
$2.71
$2.81
1-Wochen-Bereich:
$2.71
$3.07
52-Wochen-Spanne:
$2.56
$6.4399
Altimmune Inc Stock (ALT) Company Profile
Firmenname
Altimmune Inc
Sektor
Branche
Telefon
(240) 654-1450
Adresse
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
2.735 | 595.22M | 36,000 | -91.08M | -71.67M | -0.9376 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Hochstufung | Goldman | Sell → Neutral |
| 2026-03-18 | Eingeleitet | Truist | Buy |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-07-10 | Fortgesetzt | Goldman | Sell |
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-11-12 | Eingeleitet | UBS | Buy |
| 2024-04-29 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-01-24 | Eingeleitet | Goldman | Neutral |
| 2023-03-22 | Herabstufung | Goldman | Buy → Neutral |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-11 | Eingeleitet | Guggenheim | Buy |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-11-12 | Bestätigt | B. Riley Securities | Buy |
| 2020-09-25 | Eingeleitet | B. Riley FBR | Buy |
| 2020-08-14 | Eingeleitet | Evercore ISI | Outperform |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-02-24 | Fortgesetzt | ROTH Capital | Buy |
| 2019-07-19 | Eingeleitet | ROTH Capital | Buy |
| 2017-10-09 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Altimmune Inc Aktie (ALT) Neueste Nachrichten
Altimmune Details Pemvidutide’s Path Toward a Liver-Disease Franchise - Yahoo Finance
Altimmune at Stifel 2026 Virtual Cardiometabolic Forum: liver push By Investing.com - Investing.com Canada
Altimmune Appoints Richard Menziuso as Principal Accounting Officer - The Globe and Mail
Tangible book value per share of Altimmune, Inc. – HAN:3G0 - TradingView
Altimmune Inc. (ALT) Steadies Near $2.97 as Traders Watch $3.12 CeilingLow Volatility Picks - siam.in
ETFs Investing in Altimmune, Inc. Stocks - TradingView
Form 8K Altimmune Inc For: 29 September By Investing.com - Investing.com Nigeria
Altimmune Names Richard Menziuso Principal Accounting Officer - Minichart
Altimmune appoints Richard Menziuso as vice president and principal accounting officer - Investing.com Nigeria
Altimmune appoints Richard Menziuso as VP, Global Controller and Principal Accounting Officer - TradingView
Altimmune, Inc. Announces Appointment of Richard Menziuso as Global Controller and Principal Accounting Officer, Effective September 29, 2026 - marketscreener.com
Altimmune Stock Price Forecast. Should You Buy ALT? - StockInvest.us
ALT Stock Reverses Early Gains On Positive Alcohol Use Trial — But Wall Street, Retail Investors Dismiss Selloff - Stocktwits
ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside? - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Evercore Maintains Altimmune(ALT.US) With Buy Rating, Cuts Target Price to $17 - Moomoo
Altimmune’s Phase 3 MASH Trial Puts Pemvidutide in the Spotlight for Investors - TipRanks
ALT Maintained by Evercore ISI Group -- Price Target Lowered to $17 - GuruFocus
Altimmune to Participate in Stifel Cardiometabolic Forum - The Manila Times
Altimmune, Inc. (ALT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Altimmune Inc. (ALT) Edges Higher to $3.27 as Shares Hold Mid-RangeETF Outflow Streak - siam.in
Altimmune, Inc. (ALT) Stock Analysis: Biotech's Potential 431.55% Upside Draws Investor Attention - DirectorsTalk Interviews
Altimmune (ALT) exec gains stock as 24,000 RSUs vest - Stock Titan
Altimmune’s Investigational Therapy For Alcohol Use Disorder Meets Primary Endpoint – ALT Stock Jumps 10% - Stocktwits
Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report? - Yahoo Finance
Altimmune at Wells Fargo healthcare conference: pemvidutide push By Investing.com - Investing.com Canada
Altimmune’s (ALT) Three Liver Trials Move Forward At Once - Yahoo Finance
Altimmune Inc. (ALT) Peer Comparison – Compare with Others - Value Research
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference - marketscreener.com
Altimmune (ALT) Trading: Closes 5.42% Higher at $3.11 in the Current Update; Price Setup: the Supplied Trading Band Runs From $2.95 to $3.27 in Latest TradingValue Area Low - careplusvn.com
Altimmune (NASDAQ:ALT) Trading Up 9.2%Should You Buy? - MarketBeat
ALT Stock Drops Pre-Market On Dilution Fears – Retail Calls It A ‘Horror Story’ - Stocktwits
Altimmune Inc (ALT) News, Articles, Events & Latest Updates - Stocktwits
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger? - Yahoo Finance
Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus - Yahoo Finance
HC Wainwright Estimates Altimmune's Q3 Earnings (NASDAQ:ALT) - MarketBeat
LULU, LCID, ALT Stocks Hit 52-Week Lows Today: What's Driving The Selloff? - Stocktwits
H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Altimmune (ALT) Rises 2.08% to $2.94 as Shares Hold Above Key SupportActive ETF Flow - Vinanet
Altimmune Inc (ALT) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
9 Health Care Stocks Whale Activity In Today’s Session - Benzinga
Altimmune (ALT) Q2 2026 Earnings Call: PERFORMA Starts, Cash Reaches $519M - TradingKey
ALT|Altimmune Inc|Price:3.110|Chg%:+0.160 - TradingKey
Altimmune (ALT) President and CEO Jerome Durso Buys 15,000 Shares - GuruFocus
Altimmune CEO Jerome Benedict Durso Buys 15,000 Shares at $2.95 Each - Kalkine Media
Altimmune (ALT) CEO Jerome Durso purchases 15,000 shares at $2.95 each - Stock Titan
Altimmune: Pemvidutide Performs, But A Long Wait Ahead (NASDAQ:ALT) - Seeking Alpha
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus - The Globe and Mail
Barclays Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Altimmune Inc RECLAIM Phase 2 Trial in AUD Topline Results Conference Call Transcript - GuruFocus
Q3 2025 Altimmune Inc Earnings Call Transcript - GuruFocus
Finanzdaten der Altimmune Inc-Aktie (ALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Altimmune Inc-Aktie (ALT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Durso Jerome Benedict | President and CEO |
Aug 13 '26 |
Buy |
2.95 |
15,000 |
44,250 |
62,500 |
| GILL JOHN | Director |
Apr 06 '26 |
Buy |
3.41 |
9,200 |
31,350 |
21,700 |
| WEAVER GREGORY L | Chief Financial Officer |
Apr 01 '26 |
Buy |
3.15 |
10,000 |
31,499 |
38,078 |
| Durso Jerome Benedict | President and CEO |
Apr 01 '26 |
Buy |
3.14 |
15,000 |
47,100 |
47,500 |
| WEAVER GREGORY L | Chief Financial Officer |
Mar 06 '26 |
Buy |
3.54 |
5,000 |
17,700 |
28,078 |
| Durso Jerome Benedict | President and CEO |
Mar 06 '26 |
Buy |
3.54 |
20,000 |
70,790 |
32,500 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '26 |
Option Exercise |
0.00 |
7,775 |
0 |
115,153 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '26 |
Option Exercise |
0.00 |
9,275 |
0 |
104,670 |
| Garg Vipin K | Director |
Jan 30 '26 |
Option Exercise |
0.00 |
26,775 |
0 |
429,225 |
| Jordt Raymond M | Chief Business Officer |
Jan 27 '26 |
Option Exercise |
0.00 |
15,850 |
0 |
69,765 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):